Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capmatinib + neratinib
- Development stage
- Discontinued
- Lead developer
- Puma Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Capmatinib + neratinib is an investigational oral combination therapy being studied for the treatment of metastatic or locally advanced breast cancer, particularly HER2-positive subtypes. Capmatinib is a selective MET tyrosine kinase inhibitor, while neratinib is an irreversible pan-HER tyrosine kinase inhibitor targeting HER1 (EGFR), HER2, and HER4. The rationale for combining these agents stems from the potential to overcome resistance mechanisms in tumors that involve both MET and HER family signaling pathways. This combination aims to provide enhanced antitumor activity by simultaneously inhibiting multiple oncogenic drivers involved in breast cancer progression[1][2]. Clinical trials are ongoing to evaluate safety and efficacy.
- Other names
- neratinib + capmatinib
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on capmatinib + neratinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capmatinib + neratinib.